Salmeterol Xinafoate and Fluticasone Propinate Powder for Inhalation for Asthma
Status:
Unknown status
Trial end date:
2018-10-31
Target enrollment:
Participant gender:
Summary
assess the efficacy and safety of Salmeterol Xinafoate and Fluticasone Propinate Powder for
inhalation (50ug/250ug) in combination with seretide to patients with Asthma.
a randomized, double-blind, double-dummy, positive-controlled, parallel-group trail.
Phase:
Phase 3
Details
Lead Sponsor:
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd
Treatments:
Fluticasone Fluticasone Propionate, Salmeterol Xinafoate Drug Combination Fluticasone-Salmeterol Drug Combination Salmeterol Xinafoate